Increased serum levels of matrix metalloproteinase‐9 predict clinical outcome of patients with early B‐cell chronic lymphocytic leukaemia
- 19 May 2003
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 70 (6) , 373-378
- https://doi.org/10.1034/j.1600-0609.2003.00064.x
Abstract
F1000Prime Recommended Article: Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia.Keywords
This publication has 25 references indexed in Scilit:
- Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemiaBlood, 2002
- Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factorsBlood, 2002
- V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemiaBlood, 2002
- Relationship between p53 dysfunction, CD38 expression, andIgVH mutation in chronic lymphocytic leukemiaBlood, 2002
- B-CLL: is the enigma of disease heterogeneity about to be revealed?Blood, 2002
- Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferonsLeukemia, 2002
- Chronic Lymphocytic LeukemiaHematology-American Society Hematology Education Program, 2002
- Genomic Aberrations and Survival in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2000
- Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosisLeukemia, 1997
- Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significanceBritish Journal of Haematology, 1986